N@N

Zalicus to Present Corporate Updates in October

_{//health-fitness.news-articles.net/content/2010/ .. cus-to-present-corporate-updates-in-october.html}
^{Published in Health and Fitness on Wednesday, September 29th 2010 at 5:10 GMT by Market Wire}  

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Justin Renz, Senior Vice President and CFO is scheduled to present at the Ninth Annual BIO Investor Forum at 10:30am PT on October 6, 2010, at the San Francisco Palace Hotel. Mr. Renz will also present at an investor luncheon hosted by the National Association of Stockbrokers at 1pm PT on October 6, 2010 at 655 Montgomery Street in San Francisco.

About Zalicus

Zalicus Inc. (NASDAQ: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit [ www.zalicus.com ].

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, Zalicusa™ combination drug discovery technology, cHTS, and its other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like "believe," "expect," "may," "will," "should," "seek," aplana or acoulda and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the development and regulatory approval of Zalicusa™s product candidates, the unproven nature of the Zalicus drug discovery technologies, and those other risks that can be found in the "Risk Factors" section of Zalicus's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward looking statements reflect managementa™s current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

(c) 2010 Zalicus Inc. All rights reserved.